By continuing to browse the site you are agreeing to our use of cookies Continue Find out more

Clinical Accelerator

Russlan Clinical Accelerator provides clients with the best of both worlds by combining the expertise and experience of ‘Old Europe’ with the affordability of ‘New Europe’. The Isle of Man-headquartered company’s research is conducted in the British Isles and Ireland while its clinical trials take place in carefully selected investigative sites in Russia, Ukraine and the Baltics states of Latvia, Lithuania, and Estonia.

It offers a range of clinical research services to worldwide clients in the pharmaceutical, biotechnology and medical device industries. Its services extend from protocol development and regulatory affairs through clinical conduct to data management, biostatistics and study reporting.

In the UK and Ireland, Clinical Accelerator co-operates with a network of independent and university-based clinical trial units and has access to considerable clinical research talent and expertise.

The experienced British clinical research professionals are in charge of the crucial parts of the drug development process (study design, protocol writing, project management, study analysis and report writing) and closely supervise the trials outsourced to Clinical Accelerator’s partners in Central and Eastern Europe.

Asked to detail the main advantages for clients of contracting with Clinical Accelerator, Dr Nikitin says: “In a nutshell, cost and time. We fully understand the financial burden associated with conducting clinical trials for pharmaceutical, biotechnology and device companies. Therefore, ensuring that our clinical trials are cost-effective - without quality in anyway being compromised - is one of our top priorities.

“Most of our employees in Eastern Europe are highly qualified academic physicians or pharmacologists with good personal experience in independent and industry-sponsored clinical trials. Strict procedures are employed for quality control and assurance.

“The cost of our services is among the most competitive in the world. This is achieved due to two factors: firstly, Clinical Accelerator is a lean and flat structure with very low overheads, and secondly, the location of our sites in Eastern European countries.

“The shortest possible time to market is another crucial factor for our clients. We have established systems that allow us to avoid delays in regulatory approvals process, and our experts armed with full knowledge of the clinical trial environment in our countries of operations ensure optimal selection and efficient management of sites that can deliver fast and efficient patient recruitment.”

Clinical Accelerator works only with the sites that hold full governmental accreditation and meet its own strict criteria on expertise, experience and ICH Good Clinical Practice (GCP) compliance. They also need to be able to demonstrate a proven track record of efficient patient recruitment.

In 2013 Clinical Accelerator conducted a clinical trial in patients with seasonal allergic rhinitis with the medical device Nasaval for Nasaleze, an Isle of Man-based manufacturer of medical devices. The results of the study could be used by Nasaleze for its registration and promotion purposes, including registration of its device with the Food and Drug Administration in the US. This is the first of example of two Manx companies collaborating in the field of clinical research. Both parties were extremely pleased that it was possible to establish their international collaboration in the Isle of Man and expect more co-operation to come on future clinical research projects.

Website: www.clinicalaccelerator.com

Tel: +44 (0)843 289 3055

Email: n.nikitin@clinicalaccelerator.com

Manx Technology Group